In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As FDA Posts Waivers, House Okays Bill To Ban Panel Members With Conflicts

This article was originally published in The Gray Sheet

Executive Summary

FDA has begun publishing conflict of interest waivers on its website for outside experts prior to their participation in advisory panel meetings, even as lawmakers continue to push for legislation that would ban individuals with conflicts from participating at all

You may also be interested in...



Advisory Panel Conflict Waivers To Stay; FDA Will Provide Clarity On Process

FDA's plan for improving its advisory committee member selection process focuses on increasing the transparency and consistency of the existing process rather than a more extensive overhaul

Advisory Panel Conflict Waivers To Stay; FDA Will Provide Clarity On Process

FDA's plan for improving its advisory committee member selection process focuses on increasing the transparency and consistency of the existing process rather than a more extensive overhaul

MDMA Annual Meeting In Brief

CED is coming soon: Revised draft guidance on CMS' coverage-with-evidence development policy is expected out within "weeks," agency Administrator Mark McClellan said June 15 at the Medical Device Manufacturers Association annual meeting in Washington, D.C. Despite rumors following the first draft guidance that CED was dead in the water due to concerns about basing coverage on patient consent, the new version will address the issue (1"The Gray Sheet" May 8, 2006, p. 7). "We want to get this right," McClellan said...

Related Content

UsernamePublicRestriction

Register

MT023583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel